Triglyceride-glucose index in the prediction of adverse cardiovascular events in patients with premature coronary artery disease: a retrospective cohort study

Table 4 Univariate Cox regression analyses for MACE

Variables	HR	95%CI	p-value
Age	0.99	0.96–1.02	0.410
Male	0.84	0.57–1.25	0.393
BMI	1.07	1.01–1.13	0.033
LVEF	0.84	0.12–5.97	0.861
Admission for MI	1.10	0.72–1.67	0.655
Multivessel disease	1.71	1.14–2.57	0.009
GS	1.01	1.00–1.01	0.119
Current Smoking	1.56	1.04–2.32	0.032
Current Drinking	1.25	0.80–1.95	0.335
FH-CAD	1.46	0.97–2.21	0.073
DM	2.16	1.43–3.28	< 0.001
Hypertension	1.75	1.16–2.66	0.008
Hyperlipidemia	1.20	0.80–1.80	0.390
FPG	1.16	1.09–1.25	< 0.001
TC	1.13	0.98–1.30	0.091
TG	1.11	0.92–1.34	0.286
LDL-C	1.23	1.03–1.48	0.024
HDL-C	0.64	0.29–1.42	0.272
eGFR	1.00	0.99–1.01	0.672
UA	1.00	1.00–1.00	0.759
Antiplatelet drugs	0.79	0.32–1.96	0.618
Stains	0.37	0.18–0.76	0.007
Beta-blockers	0.77	0.52–1.15	0.199
ACEI/ARB	1.02	0.69–1.51	0.927
Hypoglycemic drugs	2.26	1.48–3.47	< 0.001
TyG index	1.96	1.41–2.73	< 0.001
TyG index (Per SD)	1.46	1.22–1.76	< 0.001

MACE major adverse cardiovascular events, HR Hazard ratio, CI Confidence interval, BMI body mass index, LVEF left ventricle ejection fraction, MI myocardial infarction, GS Gensini score, FH-CAD family history of coronary artery disease, DM diabetes mellitus, FPG fasting plasma glucose, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, eGFR estimated glomerular filtration rate, UA uric acid, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, TyG index triglyceride-glucose index, SD standard deviation
p values in bold are < 0.05

ISSN: 1475-2840